Author Login

Correspondence to Author: Maaike Buskermolen¹, MD; Saskia M Rombach², MD, PhD; Mirjam E.J. van Velthoven1 , MD PhD. 

1. Uveitis Service, Rotterdam Eye Hospital, Rotterdam, The Netherlands.
2. Department of Internal Medicine, Allergy and Immunology, Erasmus University Medical Centre, Rotterdam, The Netherland

DOI: 10.52338/joed.2025.4966

Abstract:

Purpose: Birdshot chorioretinopathy (BSCR) is a chronic, bilateral, auto-immune, posterior uveitis. Through this BSCR case, we investigated the value of angiographic follow-up, after starting immunomodulatory therapy (IMT).
Case report: Upon BSCR diagnosis, a 46-year-old male patient started IMT (adalimumab + methotrexate). At 8 months, we observed clinical quiescence. Angiographically, we observed complete disappearance of the typical choroidal lesions within the first year, but retinal vasculitis persisted to be present up to 2 years to date. Therefore, we continued IMT.
Conclusions: This BSCR case report shows that, even while treated with intensive IMT with adalimumab from onset and despite apparent clinical remission, regular angiographic follow-up revealed incomplete remission after 2 years, especially the retinal vasculitis component. Therefore, we recommend cautiously tapering of IMT and regular angiography for monitoring.

Citation:

Dr. Maaike Buskermolen, Birdshot Chorioretinopathy Treated With Adalimumab And Methotrexate From Onset: The Value Of Regular Angiographic Follow-Up. Journal of Ophthalmology and Eye Disorders 2025.